Holen Sie sich die Stockscreener-App
4.71
3.06%
0.14
Schlusskurs vom Vortag:
$4.57
Offen:
$4.6
24-Stunden-Volumen:
1.46M
Relative Volume:
1.04
Marktkapitalisierung:
$1.80B
Einnahmen:
$775.09M
Nettoeinkommen (Verlust:
$-58.68M
KGV:
-35.52
EPS:
-0.1326
Netto-Cashflow:
$64.06M
1W Leistung:
+13.49%
1M Leistung:
+6.08%
6M Leistung:
-44.59%
1J Leistung:
-26.75%
1-Tages-Spanne:
$4.59
$4.89
1-Wochen-Bereich:
$4.19
$4.89
52-Wochen-Spanne:
$4.09
$9.2599
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Vergleichen Sie GDRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
4.71 | 1.80B | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
223.04 | 36.21B | 2.66B | 665.91M | 1.08B | 4.05 |
|
SOLV
Solventum Corp
|
74.02 | 12.79B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
DOCS
Doximity Inc
|
55.52 | 10.37B | 516.85M | 174.11M | 217.38M | 0.87 |
|
HQY
Healthequity Inc
|
104.74 | 9.08B | 1.15B | 96.70M | -161.99M | 1.09 |
|
TEM
Tempus Ai Inc
|
47.64 | 7.50B | 640.44M | -743.28M | -206.93M | -11.29 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
Short Interest in GoodRx Holdings, Inc. (NASDAQ:GDRX) Declines By 5.8% - MarketBeat
GoodRx Holdings, Inc. Announces CFO Changes, Effective January 17, 2025 - Marketscreener.com
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Barclays PLC Grows Position in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Acquired by Barclays PLC - MarketBeat
GoodRx Holdings announces CFO resignation; shares drop - MSN
GoodRx (NASDAQ:GDRX) Stock Price Down 8.4% Following Analyst Downgrade - Defense World
GoodRx stock falls on CFO resignation news By Investing.com - Investing.com Canada
More Zero-cost Virtual Healthcare Appointments Available to Those Affected by Wildfires in Southern California - GlobeNewswire Inc.
GoodRx Holdings CFO Resigns, Interim CFO Appointed - TipRanks
GoodRx (NASDAQ:GDRX) Price Target Lowered to $6.25 at Citigroup - MarketBeat
GoodRx (NASDAQ:GDRX) Stock Price Up 5.8%Should You Buy? - MarketBeat
GoodRx (NASDAQ:GDRX) Price Target Lowered to $6.00 at KeyCorp - MarketBeat
Assessing GoodRx Holdings: Insights From 4 Financial Analysts - Benzinga
GoodRx: A Business In Transition, But It Has Likely Reached Its Low (Rating Upgrade) - Seeking Alpha
GoodRx Unleashes “GoodRx for Pets,” Simplifying Access and Reducing Costs for Pet Medications - Marketscreener.com
GoodRx Unleashes "GoodRx for Pets," Simplifying Access and Reducing Costs for Pet Medications - Quantisnow
WM Technology Names Former Cerebral CTO Sarah Griffis to Lead Technology Innovation - StockTitan
Jane Street Group LLC Sells 38,269 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
GoodRx (NASDAQ:GDRX) Sees Strong Trading VolumeHere's Why - MarketBeat
GoodRx Holdings, Inc. (NASDAQ:GDRX) Short Interest Update - MarketBeat
Exploring 3 Prominent High Growth Tech Stocks In The United States - Yahoo Finance
Barclays PLC Has $973,000 Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
Sanctuary Advisors LLC Invests $85,000 in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
GoodRx Taps Pharmacy Benefits Exec as CEO - Los Angeles Business Journal
State Street Corp Sells 262,022 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) - MarketBeat
State Street Corp Decreases Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
GoodRx (NASDAQ:GDRX) Trading Up 2%Here's What Happened - MarketBeat
GoodRx stock removed from Raymond James' Favorites list - Investing.com India
GoodRx stock removed from Raymond James’ Favorites list By Investing.com - Investing.com Nigeria
GoodRx stock removed from Raymond James' Favorites list By Investing.com - Investing.com South Africa
Raymond James adds UnitedHealth, drops GoodRx from favorites list - Seeking Alpha
Franklin Resources Inc. Makes New $5.68 Million Investment in GoodRx Holdings, Inc. (NASDAQ:GDRX) - MarketBeat
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
GoodRx to Present at J.P. Morgan's Prestigious Healthcare Conference in January 2025 - StockTitan
GoodRx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
GoodRx Holdings, Inc. Appoints Wendy Barnes as CEO Starting January 1, 2025 - Marketscreener.com
GoodRx names new CEO - Houston Business Journal
GoodRx names Wendy Barnes as new CEO and President By Investing.com - Investing.com Australia
Morgan Stanley Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price - MarketBeat
GoodRx stock rises 5% after new CEO appointment By Investing.com - Investing.com Australia
GoodRx Report: 70% of U.S. Counties Face Critical Endocrinologist Shortage, 50M Americans Affected - StockTitan
GoodRx stock rises 5% after new CEO appointment - Investing.com
GoodRx appoints PBM veteran Wendy Barnes as CEO—Wells Fargo bullish on stock - Investing.com
GoodRx names Wendy Barnes as new CEO and President - Investing.com
GoodRx Holdings Appoints Wendy Barnes as CEO - TipRanks
GoodRx Names Wendy Barnes as New CEO - MarketWatch
GoodRx appoints Wendy Barnes as new CEO - Investing.com
GoodRx Appoints Healthcare Industry Veteran, Wendy Barnes, as New Chief Executive Officer - Nasdaq
Charles Schwab Investment Management Inc. Boosts Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
7.02%
1.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):